Effect of Ketone Esters in Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04477161|
Recruitment Status : Completed
First Posted : July 20, 2020
Last Update Posted : January 4, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease Ketosis||Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink Other: Stool Sample||Not Applicable|
Parkinson's Disease (PD) is a debilitating progressive neurodegenerative disorder, second in frequency only to Alzheimer's disease, affecting around 10 million people worldwide. PD is characterized by loss of dopaminergic cells in substantia nigra and the accumulation of Lewy bodies. There is no disease modifying treatment or cure for the disease and management strategies focus on symptomatic treatment. One of the proposed mechanisms for the dopaminergic neurons degeneration in sporadic Parkinson's disease cases is related to compromise cellular bioenergetics, resulting in excessive production of reactive oxygen species (ROS) that leads to oxidative stress. Numerous studies have identified mitochondrial dysfunction as the central pathological features of both genetic and sporadic PD. Mitochondrial dysfunction can also increase inflammation which is associated with PD and Lewy Body formation. Elevated plasma ketones have been shown to enhance energy reserves, ATP levels and the expression of many enzymes involved in multiple metabolic pathways in the mitochondria. This pilot study aims to assess the effect of an exogenous ketone supplement on functional performance in people with PD. Changes in inflammatory makers will also be assessed. Participants will ingest the exogenous ketone supplement four times per day for four weeks. Participants will undergo neurological, functional, and cognitive assessments prior to and after the four-week intervention. Dietitians will follow up with participants weekly for compliance and counseling. Diet will be assessed throughout the study using the automated self-administered 24-hour dietary recall. After the four week intervention, a two-week "washout" period will be observed before reassessing functional and cognitive performance again.
Additionally, the study would like to establish the extent to which the use of Ketone esters impact the gut microbiota. Gut microbita composition in PD has been associated with symptoms and treatment efficacy.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||pilot, prospective, single-arm, single-center study|
|Masking:||None (Open Label)|
|Official Title:||Effect of Ketone Esters on Parkinson Disease: A Pilot, Prospective Trial.|
|Actual Study Start Date :||September 5, 2019|
|Actual Primary Completion Date :||November 5, 2020|
|Actual Study Completion Date :||November 5, 2020|
Experimental: Ketone Intervention
Subjects will take the Ketone Ester Elite Endurance Nutrition Drink. They will drink 1 bottle 4 times daily for 4 weeks
Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink
Subjects will take one bottle four times daily for four weeks
Other: Stool Sample
Subjects will provide a stool sample at 2 timepoints.
- Changes in serum Ketones [ Time Frame: Baseline up to 4 months ]by measuring the beta-hydroxybutyrate/serum glucose levels in blood at baseline and four months
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||40 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Physician-diagnosed Parkinson's Disease
- 40-75 years of age
- On stable dopaminergic therapy
- Willing and able to complete the informed consent form in English
- Willing to consume the study supplement four times each day during the 4-week intervention period
- Willing to complete all dietary recalls over approximately 6 weeks
- Willing to complete all daily and weekly questionnaires throughout the six weeks.
- Does not meet the above criteria
- Atypical or secondary Parkinsonism
- BMI >30
- Rheumatological or other inflammatory conditions
- Following of the ketogenic diet
- History of ulcer disease
- History of irritable bowel disorder or irritable bowel syndrome
- Currently taking any medication that could affect stool formation.
- Diagnosis of Diabetes mellitus Type 1 or Type 2
- Currently smoking (including vaping) tobacco products.
- Women who are lactating, know that they are pregnant, or are attempting to get pregnant.
- Note: a pregnancy test will be administered prior to initiating consumption of the study supplement. Women who are pregnant will be withdrawn from the study at that time.
- Use of another investigational product within 3 months of the initial visit.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04477161
|United States, Florida|
|Fixel Institute for Neurological Diseases|
|Gainesville, Florida, United States, 32608|
|Responsible Party:||University of Florida|
|Other Study ID Numbers:||
Ketone in PD
IRB201901326 ( Other Identifier: UF IRB )
OCR24402 ( Other Identifier: UF OnCore )
|First Posted:||July 20, 2020 Key Record Dates|
|Last Update Posted:||January 4, 2022|
|Last Verified:||January 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||Participant data will be shared with collaborators on project here at the University of Florida and only de-identified data will be released with IRB approval.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases